While Biden's antitrust regime has significantly stepped up reviews and litigation, recent back-to-back defeats highlight how its bark can be worse than its bite.
with its $13 billion acquisition of Change Healthcare, denying a U.S. Justice Department effort to block the deal.
The ruling in UHC's favor comes just weeks after a Federal Trade Commission administrative judge denied that agency's efforts to block Illumina from buying Grail, although Illumina subsequently lost a similar case in front of the European Commission.These back-to-back defeats highlight how while Biden's antitrust regime talks a big game, and has significantly stepped up reviews and litigation, its bark can be worse than its bite.
Even companies like Amazon, which just agreed to buy both One Medical and iRobot, despite being explicitly in the regulatory crosshairs. Or Adobe, which must know that its Figma deal isYes, there have been Biden-era mergers scuttled pre-trial, with buyers deciding the risk, cost and time outweighed the reward.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Nearly 1.1M residents in N.J. could benefit from student loan forgiveness program, White House saysPresident Joe Biden announced a plan to forgive as much as $20,000 in student loans.
続きを読む »
Is the Pandemic Finally Ending? Biden Says It's 'Over,' but Others Aren't So SurePresident Joe Biden said the pandemic is over, which has left many confused.
続きを読む »
Is the pandemic over? One public health expert says 'no'A recent statement by President Joe Biden raised some eyebrows in the public health community.
続きを読む »
Border Wall Construction Is Starting Up Again Next MonthThe border wall championed by President Donald Trump will resume construction next month—and is set to stay.
続きを読む »